Biogen, TIGET in hemophilia gene therapy tie-up

Biogen Idec Inc. (NASDAQ:BIIB) started a collaboration with Fondazione Telethon (Milano, Italy) and Ospedale San Raffaele (Milano, Italy) to develop gene therapies to treat hemophilia A and B.

Biogen will pay the San Raffaele-Telethon

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE